Pfiz­er re­files Seagen ac­qui­si­tion pa­per­work, deal still ex­pect­ed to close with­in the year

Pfiz­er’s de­ci­sion to re­file the pa­per­work for its $43 bil­lion ac­qui­si­tion of Seagen like­ly al­lows the drug­mak­er to pro­vide more in­for­ma­tion about the deal to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER